Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

First-in-human trial of EVerGel

Next Previous
Trial Profile

First-in-human trial of EVerGel

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 18 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Exosome gel therapeutic-EVerZom (Primary)
  • Indications Crohn's disease
  • Focus Adverse reactions; First in man

Most Recent Events

  • 18 Nov 2025 New trial record
  • 14 Nov 2025 According to EVerZom media release, company announced the closing of a 10 million fundraising round with Capital Grand Est, the European Innovation Council (EIC) Fund, Sorbonne Venture by Audacia and Aloe Private Equit, Paris Business Angels, the Capital Cell platform, and several family offices. This capital will enable EVerZom to launch its first clinical trial of EVerGel™ in 2026,
  • 14 Oct 2025 According to EVerZom media release, the trial is expected to begin in 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top